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The rise of malignant neoplasm morbidity rate is partially due to morbidity rate increase of 
Hodgkin's disease (HD) and, especially, of non-Hodgkin lymphomas (NHL). Classical clinical 
manifestations related to application of antibiotics and corticosteroids and present lymphade-
nomegaly are changing their kind to a certain extent. New concepts concerning pathogenesis 
(mainly of HD) together with therapeutic results achieved in local stages of these diseases make 
the problem of early and timely diagnosis, of specifying of morphological variant and clinical 
stage both extraordinarily actual, indeed. 
The purpose of the present paper is to summarize our experience concerning timely and pre-
cise diagnosis of lymphoproliferative diseases. 
Material and Methods 
Diagnostic terms were examined in a total of 412 patients with HD and NHL. 
With a view to timely diagnostics and specifying of morphological variant a comparative 
cyto-histomorphological and ultrastructural investigation of lymph node biopsies from 116 pa-
tients was carried out. Preliminarily, lymph puncture was performed and after biopsy an im-
print for cytological and cytochemical investigation was taken. The following cytochemical me-
thods were used: express staining with acridine-orange, staining for nucleoli (in our own modifi-
cation), for non-specific esterase after Undritz and for acid esterase, as well as direct immuno-
fluorescence. 
A new biochemical criterion with high information value for evaluation of the activity of the 
disease was introduced, namely blood histamine level (determined spectrophotofluorimetrical-
ly after the method of W. Lorenz et al. (1970). 
A complex programme for patients' examination was elaborated. It included routine para-
clinical and roentgenological methods, bone-marrow investigation, trepanobiopsy, echographic 
investigation of abdomen, endoscopic methods (fibrobronchoscopy and rectoromanoscopy), 
parameters for evaluation of both cell-mediated and humoral immunity as well. 
Data were processed after the method of variation and non-parametric analyses. A mathe-
matical method for probability evaluation of discriminative capacity of a given criterion was 
applied. 
Results and Discussion 
1. Time limits for diagnosis 
Diagnostic stages are followed-up by means of inquiries with 324 HD patients and 92 NHL 
ones. The first stage — from initial manifestations of the illness until seeking physician's aid — 
is at the average 3.33 ± 0.25 months long. There is a reliable difference of duration for 1st,-
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Ilnd stage (p < 0.05) and, especially, for Ist-HIrd and ist-ivth one (p < 0.001) in the clinical 
course of the disease. The second stage - from the first physician's examination until diagnosti­
cating — is at the average 3.38 ± 0.22 months long and provides information about oncological 
purposefulness of physicians from the public health services. The most important, third stage -
from initial complaints to diagnosticating - which does not present any summation of the first 
two ones, is at the average 5.86±1.76 months long. It is shorter in patients of 1st a n ( ] 2nd clinical 
stage - 5.26±1,76 months and 4.97±0.70 monts, respectively, but longer - 6.94±0.53 months in 
patients of 3rd stage, especially of 4th one - 8.48±0.87 months (P<0.001). This stage is the long­
est one with patiei ts of lymphoexhausted variant (p<0.001). Data presented show that in Bulga­
ria, like in other countries ( 1 , 2, 4, 5) HD is diagnosed averagely half a year after initial clinical 
manifestations, i.e. after a period of undoubted progress of the disease. More than half the pa­
tients (57.67. per cent) are diagnosed during generalized 3rd 4th stages. The reasons for late 
diagnosis of HD patients are as follows: non-timely seeking physician's aid on the occasion of 
lymphadenomegaly, incorrect initial clinical diagnosis (in 54.49 per cent of the cases) (fig. 1), 
existance of so-called "masks of disease", performing of antibiotic and corticohormonal treat­
ment inducing false fade-away of symptomatics, cir.d more seldom - a morphological error (in 
6.12 per cent of the patients). 
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Fig. 1. Incorrect initial diagnosis of lymphoprolifeгаtive diseases 
1 - lymphadenopathy; 2 - tbc; 3 - lung disease; 4 - thyrojd gland disease; 5 - respiratory diseases, sepsis; 
6 - dermatoses; 7 - radiculitis; 8 - surgical disease; 9 - cardiovascular disease; 10 - normal 
The mean time limit for diagnosis is 10.5 ± 0.92 months in NHL patients with low malignan­
cy degree but 2.3 ± 0.031 months in NHL ones wiht higher malignancy degree. Clinical sym­
ptomatics is rather more manifested in these patients which has made them seek earlier physi­
cian'a aid and thus a more timely diagnosis of their disease. 
2. Cyto-, histomorphological and ultrastructural study 
The comparison between cytological and histological examination reveals a coincidence be­
tween cytological and histological diagnosis in 79.80 per cent of the patients. Total in coinci­
dence percentage of 20.20 is mainly due to fine-needle aspiration biopsy (in 12.3 per cent) 
while that̂  due to imprints is only 7.9. per cent. Histological diagnosis has not been possible 
without cytological investigation in 1.98 per cent of the cases. On the one hand, cytochemical 
methods enable specifying of morphological variant, especially in NHL patients, and, on the 
other hand, establishing of malignancy degree. 
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The ultrastructural study of lymph nodes from HD and NHL patients reveals specific diffe­
rences in dependence on their histological variant. Cellular atypia increases with pathological 
process advancing. It is particularly well-expressed in patients with evolution course of the di­
sease. Ultrastructural peculiarities of lymph node metastases from tumours of epithelial origin 
(desmosomes, basal bodies) can be used as additional criteria in the differential diagnosis of lym-
phoproliferative diseases. 
3. Blood histamine level 
In relation to recent data about an eventual role of histamine in numerous diseases characte­
rized by disturbances of the immune system (10) and, more concretely, about its immuno-
modulating role in HD (6), we followed-up blood histamine level in a total of 116 patients, of 
which 73 with HD and 43 with NHL. It was established that this level is about 3 times lower as 
compared with that of healthy individuals (i.e. 0.031 ± 0.002 mkg/ml and 0.072 ± 0.002 mkg/ 
ml, respectively) only in HD patients with active pathological process. After treatment, how­
ever, blood histamine level increases and during remission this level reaches the normal limits 
(0.089 ± 0.005 mkg/ml). We calculated the discriminative capacity of this criterion and it was 
0.040 mkg/ml. This means that at borderline states blood histamine reduction below 0.040 
mkg/ml is an alarming finding. The information value of newly-introduced parameter "blood 
histamine level" is compared with laboratory indexes commonly used at present (according to 
Ann Arbor Classification, 1971) (9). By using of a method for probability modelling of states 
of biological activity and remission the maximal recognition capacity of combinations of labo­
ratory indexes concerning these two states is determined (8). This enables timely starting of 
treatment in relapse of the disease as well as its cessation. Other authors (3) also report a search 
for new additional criteria for evaluation of HD patients' state and for determining the progno­
sis of the illness. 
4. Complex programme for patient's examination 
This programme elaborated by us consisting in the methods mentioned above for specifying 
of pathological process generalization caused stage change with 38 per cent of HD and NHL 
patients. 
We can conclude that diagnostic specifying of lymph op roliferative diseases is a responsible 
and difficult physician's task. While at the beginning the question is posed at the early and 
proof morphological diagnosis, later on the specifying of clinical stage is required. Maximal 
shortening of diagnostic time limits, introduction of modern methods for evaluation of genera­
lization and activity of the pathological process contribute to increasing effectivity of treatment 
and to prognostical improvement of these diseases. 
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К ВОПРОСУ О СВОЕВРЕМЕННОЙ И ПРЕЦИЗИОННОЙ ДИАГНОСТИКЕ 
ЛИМФОНРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ 
Р.Миткова, А. Захариев, Д. Желязков, А. Белчева 
Р Е 3 Ю М Е 
С целью ранней и своевременной диагностики лимфопролиферативных заболеваний, а также для 
прецизирования их морфологического варианта и клинического стадия, изучены сроки диагнести-
цирования больных болезнью Хочкина и больных не-хочкиновыми лимфомами. Применены сравни­
тельные цитоморфологическое, гисто морфологическое и ультраструктурное исследования биопсий 
лимфатических узлов. Применен также дополнительный биохимический критерий (уровень гиста-
мина в крови) с целью оценки активности заболевания при болезни Хочкина. Разработана наряду с 
этим расширенная про1рамма исследования больных. 
Обобщенные данные показывают, что диагностицирование лимфопролиферативных заболеваний 
требует комплексного подхода, включающего клинико-морфологические, ультраструктурные, 
биохимические и инструментальные исследования, с целью проведения'адекватной терапии и опре­
деления прогноза заболеваний. 
